Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
Key facts
- Who runs it
- Acepodia Biotech, Inc.
- Where
- Atlanta and Boston, United StatesSee the 2 sitesAlso in 2 other countries, 9 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 34 people, planned
- Started
- 1 Jan 2026
- Expected to end
- 20 Sept 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- ACE1831
- Lymphodepleting chemotherapy
- Record updated
- 2 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Signed Informed Consent
- Male or female ≥ 18 years of age
- Active IgG4-RD flare at screening with IgG4-RD Responder Index at least 2, confirmed by symptoms, labs, and/or imaging
- History of IgG4-RD involving at least 2 organs/sites, and current flare involves at least 1 organ/site (excluding lymph nodes) requiring treatment
- Elevated serum IgG4 above the upper limit of normal at screening
- Able to receive glucocorticoids for current flare and taper to 0 mg by Day -5
- Contraception agreement per protocol from screening through 24 weeks after last ACE1831 dose (no LDC) or 12 months after last LDC dose (with LDC)
- For sites in China only: prior treatment failure to glucocorticoids, one immunosuppressive agent and one biologic agent
Who cannot take part
- Recent investigational agent exposure
- Recent B-cell depleting therapy (anti-CD20/anti-CD19) unless reconstitution per protocol
- Live/attenuated vaccine within 2 months
- Significant conditions that impair ability to receive study treatment or comply
- Active/latent infection that would interfere with therapy (including HBV, HCV, HIV, TB, syphilis) or significant recent infection per protocol
- NYHA class III/IV heart disease
- Severe allergy/hypersensitivity to monoclonal antibodies or relevant study agents
- Malignancy within 5 years (protocol exceptions apply)
- Inadequate organ function/blood counts per protocol
- Predominant fibrosis in affected organs
- Known immunodeficiency state
- Pregnant or breastfeeding
Where in United States
Also in 2 other countries, 9 sites
- Emory UniversityAtlanta, United StatesContact: Acepodia Clinical TeamTaking people
- Massachusetts General HospitalBoston, United StatesContact: Acepodia Clinical TeamTaking people
About the trial
What the trial wants to find out
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)
The 2 groups in the trial
- Arm ATreatment being tested
* Cohort A1: Receives single infusion of ACE1831 (Dose Level 1) with lymphodepletion conditioning (LDC). * Cohort A2: Receives single infusion of ACE1831 (Dose Level 2) with LDC.
Treatment: ACE1831 and Lymphodepleting chemotherapy
- Arm BTreatment being tested
* Cohort B1: Receives two infusions of ACE1831 (Dose Level 1) without LDC. * Cohort B2: Receives two infusions of ACE1831 (Dose Level 2) without LDC. * Cohort E (Expansion): Two infusions of ACE1831 at the dose/regimen selected by the Safety Review Committee (SRC)
Treatment: ACE1831
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1b/2a Prospective, Open Label, Multicenter, Two-Arm Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With Immunoglobulin G4-Related Disease
- Record updated
- 2 October 2026